The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1437
ISSUE1437
March 3, 2014
Riociguat (Adempas) for Pulmonary Hypertension
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Riociguat (Adempas) for Pulmonary Hypertension
March 3, 2014 (Issue: 1437)
The FDA has approved the sGC stimulator riociguat
(rye" oh sig' ue at; Adempas – Bayer) for oral treatment
of pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension
(CTEPH) following surgery or when surgery is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.